Journal for Biophysical Chemistry
From: Model Membrane Platforms for Biomedicine: Case Study on Antiviral Drug Development
Protein | Membrane associating region | Replicase function(s) | Functional targets | Necessary for replication | Drug pipeline |
---|---|---|---|---|---|
NS2 | At least one transmembrane domain | (1) NS2–NS3 proteolytic cleavage | (1) Transmembrane domains | Noa | Preclinical |
(2) Protease active site | |||||
(3) Dimerization motif | |||||
NS3 | None | (1) Serine protease domain releases NS proteins downstream | (1) Protease active site | Yes | Phase lll/IVb |
(2) Helicase active site | |||||
(2) Helicase domain unwinds dsRNA/ssRNA | |||||
(3) NTPase active site | |||||
(4) RNA-binding region | |||||
(5) NS4A- and NS5B-interaction regions | |||||
NS4A | N-terminal transmembrane domain | (1) NS3 cofactor for proper folding and membrane localization | (1) N-terminal transmembrane domain | Yes | ibid |
NS4B | N-terminal AH | (1) Induces membranous web formation | (1) N-terminal AH | Yes | Phase I |
(2) Internal AH | |||||
(3) RNA-binding region | |||||
(4) Oligomerization motif | |||||
NS5A | N-terminal AH | Unknownc | (1) N-terminal AH | Yes | Phase Id |
(2) Domain I dimerization motif for RNA binding | |||||
(3) Core protein interaction region | |||||
NS5B | C-terminal anchor region | (1) Synthesis of viral genome RNA | (1) Polymerase active site | Yes | Phase II |
(2) Allosteric binding sites | |||||
(3) NS3- and NS5A-interaction regions | |||||
(4) RNA-binding region | |||||
(5) Oligomerization motif |